The way the health care cost's are evolving in the long run a bio-substitute will have no better financial advantage than the generic or the branded drug. An bio-better maybe would have an advantage.
We're all going to be old and Momenta will be out of money long before a Momenta bio-substitute makes it to market.
Non-interchangeable FoB’s will be distinct branded drugs with their own brand name. Whether such products are approved before or after an interchangeable FoB from MNTA/BAX does not make much difference, IMO, although it will probably happen before because the threshold for approval of such products is lower.
Market Data 
Markets 
AI
